These data also support the therapeutic interest in using the specific inhibitory agents of EGFR, PI3K/pAkt, NF-κB and/or MIC-1 for eradicating PC stem/progenitor cells and their progenies, and thereby improving the anticarcinogenic efficacy of current anti-hormonal and first-line docetaxel-based chemotherapeutic regimens against locally invasive and metastatic CRPCs and preventing the disease relapse and the death of patients. The gene discussed is NFKB1; the disease is pachyonychia congenita.